Impact Events
More| Date | Lead Company | Event | Type | Approval Change | Approval Likelihood |
|---|---|---|---|---|---|
| 7/23/26 | AstraZeneca (AZN) | Etcamah for Breast Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
| 7/23/26 | AstraZeneca (AZN) | Etcamah for HR+/HER2- Breast Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
| 7/23/26 | ANI (ANIP) | Arimidex for HR+/HER2- Breast Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
| 7/23/26 | Johnson & Johnson (JNJ) | Tecvayli for Multiple Myeloma (MM) | Subscribers Only | Subscribers Only | Subscribers Only |
| 7/23/26 | Takeda (4502) | Velcade for Multiple Myeloma (MM) | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
More| Expected Date Range | Lead Company | Drug | Expected Catalyst |
|---|---|---|---|
| 06/25/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 06/25/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 06/26/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 09/08/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 09/17/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |